California (KPSC), we evaluated FN risks associated with docetaxel/cyclophosphamide (TC) and docetaxel/carboplatin/trastuzumab (TCH) for breast cancer; leucovorin/5-fluorouracil/oxaliplatin (FOLFOX6) or capecitabine/oxaliplatin (XELOX) for colorectal cancer
Search Results
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
David Y. Oh, Alan P. Venook, and Lawrence Fong
(CRC). Chemotherapeutic agents such as oxaliplatin trigger immunogenic cell death, which leads to activation and maturation of dendritic cells (DCs) through release of small molecules, such as HMGB1 and ATP (through autophagy and endoplasmic reticulum
Brian Vicuna and Al B. Benson III
fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 . J Clin Oncol 2007 ; 25 : 3456 – 3461 . 51. Kuebler JP Wieand HS O'Connell MJ . Oxaliplatin combined with weekly bolus fluorouracil and
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
chemotherapy with the addition of oxaliplatin to 5-fluorouracil (5-FU) have resulted in improved survival in patients with metastatic colorectal cancer and those with stage III colon cancer treated with adjuvant FOLFOX (5-FU, leucovorin, oxaliplatin). 5 - 8
Diane L. Reidy-Lagunes
, liver-directed therapies, and systemic therapies. Cytotoxic therapies, such as temozolomide, fluorouracil, oxaliplatin, and streptozocin-based chemotherapy regimens, are active against some pancNETs, and can play a role in the palliation of patients with
Yifan Wang, Adeline Cuggia, Alain Pacis, Jean-Christian Boileau, Victoria A. Marcus, Zu-Hua Gao, George Chong, William D. Foulkes, and George Zogopoulos
patient was treated with FOLFIRINOX (5-FU/folinic acid/irinotecan/oxaliplatin), but his disease progressed after 6 cycles ( Figure 1A ). He received gemcitabine/nab-paclitaxel as second-line treatment and experienced a partial response. However, he
Caitlin A. Hester, Giampaolo Perri, Laura R. Prakash, Jessica E. Maxwell, Naruhiko Ikoma, Michael P. Kim, Ching-Wei D. Tzeng, Brandon Smaglo, Robert Wolff, Milind Javle, Michael J. Overman, Jeffrey E. Lee, and Matthew H.G. Katz
radiographic evidence of acute pancreatitis ( Figure 1 ). Figure 1. Study flow diagram. Abbreviations: FOLFIRINOX, 5-fluorouracil/leucovorin/oxaliplatin/irinotecan; Gem/Nab-paclitaxel, gemcitabine + nanoparticle albumin–bound paclitaxel; PDAC
Liqin Zhu, Liyuan Li, Laura Hamel, and Dolores Lopez-Terrada
lines whose parental tumors did not respond to HB standard-of-care cisplatin. They showed the same resistance to cisplatin as well as 2 other platinum-based drugs, carboplatin and oxaliplatin. PDOs derived from 2 matched primary and metastatic tumors
Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho
involvement. Given his history of radiation for prostate cancer and the presence of baseline neuropathy, he was a poor candidate for neoadjuvant chemoradiation or neoadjuvant FOLFOX (folinic acid, fluorouracil, oxaliplatin). After an in-depth discussion with
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
treatments for these cancers: taxanes (docetaxel: n=322 [32.7%]; paclitaxel: n=312 [31.6%]), platinum-based chemotherapies (oxaliplatin: n=123 [12.5%]; cisplatin: n=53 [5.4%]), thalidomide (n=87; 8.8%), and bortezomib (n=82; 8.3%). One-quarter of respondents
